期刊论文详细信息
BMC Infectious Diseases
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital
Navin Horthongkham1  Wannee Kantakamalakul1  Ranistha Ratanarat2  Pinyo Rattanaumpawan3  Anupop Jitmuang3  Nasikarn Angkasekwinai3  Susan Assanasen3  Rujipas Sirijatuphat3  Yupin Suputtamongkol3  Methee Chayakulkeeree3  Pornpan Koomanachai3  Walaiporn Wangchinda3  Yong Rongrungruang3  Nitipatana Chierakul4 
[1] Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University;Division of Critical Care, Department of Medicine, Faculty of Medicine Siriraj Hospital;Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University;Division of Respiratory Diseases and Tuberculosis, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University;
关键词: COVID-19;    Epidemiology;    Clinical characteristics;    Treatment;    Outcome;    Thailand;   
DOI  :  10.1186/s12879-021-06081-z
来源: DOAJ
【 摘 要 】

Abstract Background The epidemiology and outcomes of COVID-19 patients in Thailand are scarce. Methods This retrospective cohort study included adult hospitalized patients who were diagnosed with COVID-19 at Siriraj Hospital during February 2020 to April 2020. Results The prevalence of COVID-19 was 7.5% (107 COVID-19 patients) among 1409 patients who underwent RT-PCR for SARS-CoV-2 detection at our hospital during the outbreak period. Patients with COVID-19 presented with symptoms in 94.4%. Among the 104 patients who were treated with antiviral medications, 78 (75%) received 2-drug regimen (lopinavir/ritonavir or darunavir/ritonavir plus chloroquine or hydroxychloroquine), and 26 (25%) received a 3-drug regimen with favipiravir added to the 2-drug regimen. Disease progression was observed in 18 patients (16.8%). All patients with COVID-19 were discharged alive. Conclusions The prevalence of COVID-19 was 7.5% among patients who underwent RT-PCR testing, and 10% among those having risk factors for COVID-19 acquisition. Combination antiviral therapies for COVID-19 patients were well-tolerated and produced a favorable outcome.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:2次